| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 800 | ₹0.1 -33.33% | 15,5000% |
| 2,3250% | ₹136.55 0% | 820 | ₹0.15 0% | 2,3250% |
| 4,6500% | ₹137.5 0% | 840 | ₹0.2 0% | 44,9500% |
| 7750% | ₹103.3 0% | 850 | ₹0.25 0% | 10,8500% |
| 00% | ₹78.8 0% | 870 | ₹1 0% | 4,6500% |
| - | - | 880 | ₹0.4 0% | 24,8000% |
| 7750% | ₹78.75 0% | 890 | ₹0.5 0% | 20,9250% |
| 10,8500% | ₹67 0% | 900 | ₹0.55 -26.66% | 1,74,3750% |
| 3,1000% | ₹60.25 0% | 910 | ₹1.15 -28.12% | 44,9500% |
| 15,5000% | ₹30.5 0% | 920 | ₹1.75 -37.5% | 78,27510.98% |
| 75,9500% | ₹21.85 0% | 930 | ₹3.3 -24.13% | 82,1508.16% |
| 1,13,1508.14% | ₹15 1.69% | 940 | ₹6.4 -17.41% | 1,21,6757.53% |
| 1,72,8259.31% | ₹9.35 -7.42% | 950 | ₹10.65 -10.87% | 1,96,0751.60% |
| 2,14,67537.81% | ₹5.65 -5.04% | 960 | ₹17.05 -10.26% | 1,55,7750% |
| 1,67,400-1.36% | ₹3.2 -11.11% | 970 | ₹23.95 -9.45% | 1,00,750-1.51% |
| 3,73,550-10.90% | ₹1.8 -14.28% | 980 | ₹35.45 0% | 84,4750% |
| 3,46,4251.13% | ₹1.1 -8.33% | 990 | ₹41.7 -2.79% | 20,9250% |
| 3,88,275-6.52% | ₹0.75 -11.76% | 1,000 | ₹52.95 -3.02% | 1,19,350-3.75% |
| 62,000-1.23% | ₹0.6 0% | 1,010 | ₹61 0% | 7,7500% |
| 1,12,375-9.37% | ₹0.35 -12.5% | 1,020 | - | - |
| 57,350-5.12% | ₹0.3 -14.28% | 1,030 | - | - |
| 31,775-18% | ₹0.2 -33.33% | 1,040 | ₹66 0% | 1,5500% |
| 58,125-3.84% | ₹0.2 -20% | 1,050 | - | - |
| 98,4250% | ₹0.35 0% | 1,060 | - | - |
| 7750% | ₹1 0% | 1,070 | - | - |
| 9,3000% | ₹0.15 0% | 1,080 | ₹125.8 0% | 3,1000% |
| 1,17,025-3.82% | ₹0.1 0% | 1,100 | ₹135.85 0% | 1,5500% |
| 11,6250% | ₹0.1 0% | 1,120 | - | - |
Fortis will take charge of the entire operational and financial aspects. Hence, consolidating the hospital's performance within its network.
Operating performance remained strong with EBITDA rising 43% year-on-year to ₹490.4 crore. The EBITDA margin expanded to 22.6%, from 18.4% a year ago.
The tax demand will not affect the company’s financials or operations, it said in a regulatory filing.
Here are some of the stocks that may see significant price movement today: UltraTech Cement, Jio Financial, Avenue Supermarts, etc.
EBITDA grew 32.1% YoY at ₹375.2 crore v/s ₹284 crore, a period to period, as was the expansion of EBITDA margin at 19.5% versus 16.9% Q3 FY24.
The deal worth ₹429.37 crore involves acquiring 5,970,149 equity shares at an agreed price of ₹719.2 per share through a shareholders' agreement.
Revenue from operations saw a notable growth of 12.3%, reaching ₹1,988.4 Crore, compared to ₹1,770 Crore YoY.
Jacob Ballas and International Finance Corporation (IFC), who together with Resurgence PE own approximately 34% of the diagnostics company.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
